Lion Biotechnologies CSO Laszlo Radvanyi Co-authors Study in Clinical Cancer Research
January 12, 2015 08:00 ET
|
Lion Biotechnologies, Inc.
LOS ANGELES, Jan. 12, 2015 (GLOBE NEWSWIRE) -- Lion Biotechnologies, Inc. (LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor infiltrating lymphocytes (TIL),...
Lion Biotechnologies to Present at Biotech Showcase
January 06, 2015 08:00 ET
|
Lion Biotechnologies, Inc.
LOS ANGELES, Jan. 6, 2015 (GLOBE NEWSWIRE) -- Lion Biotechnologies, Inc. (LBIO) announced that president and CEO Elma Hawkins, PhD, will present at the Biotech Showcase on Monday, January 12, 2015....
Lion Biotechnologies Submits Investigational New Drug Application to Conduct Phase 2 Study in Metastatic Melanoma
January 05, 2015 08:00 ET
|
Lion Biotechnologies, Inc.
LOS ANGELES, Jan. 5, 2015 (GLOBE NEWSWIRE) -- Lion Biotechnologies, Inc., a biotechnology company that is developing novel cancer immunotherapies, today announced that it has filed an investigational...
Lion Biotechnologies Announces Closing of Underwritten Common Stock Offering
December 22, 2014 16:01 ET
|
Lion Biotechnologies, Inc.
LOS ANGELES, Dec. 22, 2014 (GLOBE NEWSWIRE) -- Lion Biotechnologies, Inc. (OTCQB:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor infiltrating...
Lion Biotechnologies Announces Pricing of Underwritten Common Stock Offering
December 17, 2014 09:00 ET
|
Lion Biotechnologies, Inc.
LOS ANGELES, Dec. 17, 2014 (GLOBE NEWSWIRE) -- Lion Biotechnologies, Inc. (OTCQB:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor infiltrating lymphocytes...
Lion Biotechnologies Names Elma Hawkins President, Chief Executive Officer and Director
December 15, 2014 08:00 ET
|
Lion Biotechnologies, Inc.
LOS ANGELES, Dec. 15, 2014 (GLOBE NEWSWIRE) -- Lion Biotechnologies, Inc., a biotechnology company that is developing novel cancer immunotherapies based on tumor infiltrating lymphocytes (TIL), today...
Lion Biotechnologies Announces Positive New Data From Lead TIL Melanoma Program at ASH
December 08, 2014 08:00 ET
|
Lion Biotechnologies, Inc.
LOS ANGELES, Dec. 8, 2014 (GLOBE NEWSWIRE) -- Lion Biotechnologies, Inc. (LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TILs)...
Lion Biotechnologies to Present at the Piper Jaffray 26th Annual Healthcare Conference
December 01, 2014 08:00 ET
|
Lion Biotechnologies, Inc.
LOS ANGELES, Dec. 1, 2014 (GLOBE NEWSWIRE) -- Lion Biotechnologies, Inc. (LBIO), a biotechnology company focused on the development and commercialization of novel cancer immunotherapies based on...
Lion Biotechnologies Announces Clinical Data Update at American Society of Hematology Annual Meeting
November 21, 2014 08:00 ET
|
Lion Biotechnologies, Inc.
LOS ANGELES, Nov. 21, 2014 (GLOBE NEWSWIRE) -- Lion Biotechnologies, Inc. (LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TILs)...
Lion Biotechnologies Announces Management Change
November 12, 2014 16:05 ET
|
Lion Biotechnologies, Inc.
LOS ANGELES, Nov. 12, 2014 (GLOBE NEWSWIRE) -- Lion Biotechnologies, Inc. (OTCBB:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor infiltrating lymphocytes...